CD6-CAR Tregs / City of Hope, National Cancer Institute - Bethesda - LARVOL DELTA

First-in-human trial of allogeneic CD6-CAR tregs in patients with chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation (ASH 2025) - P1 | "Median prior lines of therapy was 3.5 (range 2-7), includingbelumosudil (n=5) and ruxolitinib (n=4). No hematologic malignancy was observed, and salvagetherapy for GVHD has not been required. These early clinical findings support CD6-CAR Tregs as apromising cellular therapy with the potential to re-educate an imbalanced immune system in cGVHD."

Clinical • First-in-human • P1 data • Cardiovascular • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Hypertension • Immunology • Infectious Disease • Neutropenia • Scleroderma • Systemic Sclerosis • Transplantation • CTLA4 • IL1R1 • IL4

Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation (clinicaltrials.gov) - P1 | N=27 | Suspended | Sponsor: City of Hope Medical Center | Active, not recruiting ➔ Suspended

First-in-human • Trial suspension • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Immunology • Transplantation

Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation (clinicaltrials.gov) - P1 | N=27 | Active, not recruiting | Sponsor: City of Hope Medical Center | Recruiting ➔ Active, not recruiting

Enrollment closed • First-in-human • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Immunology • Transplantation